Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Virginia Giuffre's memoir reveals intimate details about her family life, children Omaha Steaks CEO warns American families ...

Many common home-security habits — like relying on fake cameras or leaving doors unlocked — offer comfort, not real ...

The FDA has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults.

ADT Inc. (NYSE:ADT) credited the strong results to the business’s overall efficiency, coupled with top-line growth that has created a conducive environment for future-oriented investments. The company ...

ADT Inc. (NYSE:ADT) is one of the best cheap stocks under $10 to buy now. Barclays analyst Manav Patnaik maintained a Hold rating on ADT Inc. (NYSE:ADT) on November 5, setting a $9 price target.

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

ADT reported higher Q3 earnings and cash flow driven by ADT+ adoption and operational discipline, even as attrition edged up ...

Is facial recognition the future of home security? With ADT’s Trusted Neighbor feature, you can provide controlled, ...

Google’s home security partner, ADT, has a big discount available for anyone looking to start off a new security ...

BOCA RATON, Fla. — ADT Inc. has released its financial results for the third quarter of 2025. Financial highlights for the ...

Discover ADT’s Q3 2025 earnings highlights: strong revenue growth, AI-driven efficiency, and confident outlook.